首站-论文投稿智能助手
典型文献
Breast cancer screening and early diagnosis in Chinese women
文献摘要:
Breast cancer is the most common malignant tumor in Chinese women, and its incidence is increasing. Regular screening is an effective method for early tumor detection and improving patient prognosis. In this review, we analyze the epidemiological changes and risk factors associated with breast cancer in China and describe the establishment of a screening strategy suitable for Chinese women. Chinese patients with breast cancer tend to be younger than Western patients and to have denser breasts. Therefore, the age of initial screening in Chinese women should be earlier, and the importance of screening with a combination of ultrasound and mammography is stressed. Moreover, Chinese patients with breast cancers have several ancestry-specific genetic features, and aiding in the determination of genetic screening strategies for identifying high-risk populations. On the basis of current studies, we summarize the development of risk-stratified breast cancer screening guidelines for Chinese women and describe the significant improvement in the prognosis of patients with breast cancer in China.
文献关键词:
作者姓名:
Rui Ding;Yi Xiao;Miao Mo;Ying Zheng;Yi-Zhou Jiang;Zhi-Ming Shao
作者机构:
Key Laboratory of Breast Cancer in Shanghai,Department of Breast Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Cancer Prevention,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Precision Cancer Medicine Center,Fudan University Shanghai Cancer Center,Shanghai 200032,China
引用格式:
[1]Rui Ding;Yi Xiao;Miao Mo;Ying Zheng;Yi-Zhou Jiang;Zhi-Ming Shao-.Breast cancer screening and early diagnosis in Chinese women)[J].癌症生物学与医学(英文版),2022(04):450-467
A类:
B类:
Breast,screening,early,diagnosis,Chinese,women,most,common,malignant,tumor,its,incidence,increasing,Regular,effective,method,detection,improving,prognosis,In,this,review,we,analyze,epidemiological,changes,risk,factors,associated,China,describe,establishment,strategy,suitable,patients,tend,younger,than,have,denser,breasts,Therefore,age,initial,should,earlier,importance,combination,ultrasound,mammography,stressed,Moreover,cancers,several,ancestry,specific,genetic,features,aiding,determination,strategies,identifying,high,populations,On,basis,current,studies,summarize,development,stratified,guidelines,significant,improvement
AB值:
0.531427
相似文献
Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients
Panwen Tian;Xiaoyan Zhang;Sheng Yang;Yu Fang;Hongling Yuan;Wei Li;Honglin Zhu;Fangping Zhao;Jinlei Ding;Yunshu Zhu;Sizhen Wang;Guochen Sun;Hongbin Ni;Tonghui Ma;Ting Lei-Department of Respiratory and Critical Care Medicine,Lung Cancer Treatment Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;Department of Translational Medicine,Genetron Health(Beijing)Technology,Co.Ltd.,Beijing 102206,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100005,China;Department of Thoracic Surgery,The Second Hospital of Dalian Medical University,Dalian,Liaoning 116023,China;Genetron Health(Beijing)Technology,Co.Ltd.,Beijing 102206,China;Department of Neurosurgery,The First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Neurosurgery,Nanjing Drum Tower Hospital(Nanjing Gulou Yi Yuan),The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China
Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program
Wu Zheng;Tan Fengwei;Yang Zhuoyu;Wang Fei;Cao Wei;Qin Chao;Dong Xuesi;Zheng Yadi;Luo Zilin;Zhao Liang;Yu Yiwen;Xu Yongjie;Ren Jiansong;Shi Jufang;Chen Hongda;Li Jiang;Tang Wei;Shen Sipeng;Wu Ning;Chen Wanqing;Li Ni;He Jie-Office of Cancer Screening, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Key Laboratory of Cancer Data Science, Chinese Academy of Medical Sciences, Beijing 100021, China;Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;PET-CT Center, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Department of Diagnostic Radiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
ZNF3 regulates proliferation,migration and invasion through MMP1 and TWIST in colorectal cancer
Le Du;Ning Liu;Jianfeng Jin;Meng Cao;Yuantian Sun;Xinzheng Gao;Banzhan Ruan;Shangfeng Yang;Dongsheng Ge;Yingzhuan Ye;Yinxi Zhou;Erfei Chen;Jin Yang-Hainan Provincial Key Laboratory of Carcinogenesis and Intervention;Department of Biology,Hainan Medical University,Haikou 571199,China;Department of Gastrointestinal Surgery,Hainan General Hospital,Hainan Affiliated Hospital of Hainan Medical University,Haikou 571199,China;Department of Biochemistry and Molecular Biology,Hainan Medical University,Haikou 571199,China;College of Biomedical Information and Engineering,Hainan Medical University,Haikou 571199,China;Key Laboratory of Resources Biology and Biotechnology in Western China,Ministry of Education,College of Life Sciences,Northwest University,Xi'an 710069,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。